Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-14
2006-03-14
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S050000
Reexamination Certificate
active
07012086
ABSTRACT:
Chronic infection with retroviruses, such as HIV, induce a number of metabolic derangements. The present invention relates to a method for treating retrovirus-infected subjects with niacin compounds to reverse infection induced metabolic derangements.
REFERENCES:
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4911917 (1990-03-01), Kuhrts
patent: 5023245 (1991-06-01), Kuhrts
patent: 5045537 (1991-09-01), Weidmann
patent: 5047427 (1991-09-01), Williamson
patent: 5214062 (1993-05-01), Mark et al.
patent: 5508271 (1996-04-01), Rabinoff
patent: 5716946 (1998-02-01), DeLuca
patent: 5785977 (1998-07-01), Breithbarth
patent: 5916906 (1999-06-01), Shaskan
patent: 5965167 (1999-10-01), Sanghvi et al.
patent: 5973224 (1999-10-01), Fuchs et al.
patent: 5985339 (1999-11-01), Kamarei
patent: 6020333 (2000-02-01), Berque
patent: 6020351 (2000-02-01), Pero
Murray et al, Biochemical and Biophysical Res. Comm., vol. 210(3), pp. 954-959, 1995.
Tang et al, Am. J. Epidim., vol. 138(11), pp. 937-951, 1993.
The Merck Manual of Medical Information, Berkow et al Eds. Merck, Dohm & Sharp, pp. 715, 722-723, 1997.
Brown et al, Kynurenine and Serotonin Pahtways, pp. 425-435, 1991.
Tang Alice M., et al., Dietary Micronutrient Intake and Risk of Progression to Acquired Immunodeficiency Syndrome (AIDS) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Homosexual Men, Amer. J. of Epidem., vol. 138, No. 11, 932-951 (1993).
Tang Alice M., Graham Neil MH, Saah Alfred J., Effects of Micronutrient Intake on Survival in Human Immunodeficiency Virus Type 1 Infection, Amer. J. of Epidem., vol. 143, No. 12, 1244-1256 (1996).
Krasilnikov NN, et al., Inhibitors of ADP-Ribosylation as Antiviral Drugs: Experimental Study on the Model of HIV Infection (1990).
Petley A., et al., The Pharmacokinetics of Nicotinamide in Humans and Rodents, Diabetes, 44:152-155 (1995).
Dipalma Jr., Thayer WS, Use of Niacin as a Drug, Ann. Rev. Nutr. 11:169-187 (1991).
Gisslen M., Larson M., Norkrans F., Fuchs D., Wachter H., Hagberg L., Tryptophan Concentrations Increase in Cerebrospinal Fluid and Blood After Zidovudine Treatment in Patients with HIV Type I Infection, AIDS Research and Human Retroviruses, 10(8): 947-951 (1994).
RR Brown, et al., Implications of Interferon Induced Tryptophan Catabolism in Cancer, Autoimmune Disease and AIDS, Kynuronine and Serotin Pathways, 425-435 (1991).
Murray MF, Nghiem M., Srinivasan A., HIV Infection Decreases Intracellular Nicotinamide Adenine Dinucleotide [NAD], Biochemical and Biophysical Research Communications, 212:126-131 (1995).
Murray MF, Srinivasan A., Nicotinamide Inhibits HIV-1 in Both Acute and Chronic In Vitro Infection, Biochemical and Biophysical Research Communications, (3), 210:954-959 (1995).
Skurnick JH, et al., Micronutrient Profiles in HIV-1 Infected Heterosexual Adults, J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol, 12(1):75-83, (1996).
Murray MF, Niacin as a Potential AIDS Preventive Factor, Medical Hypotheses, 53(5):375-379 (1999).
Savarino A., et al., Apoptotic DNA Fragmentation, and its In Vitro Prevention by Nicotinamide, in Lymphocytes from HIV-1 Seropositive Patients and in HIV-1-Infected MT-4 Cells, Cell Biochem. And Funct., vol. 15:171-179 (1997).
Savarino A., et al., Investigation of the Potential Role of Membrane CD38 in Protection Against Cell Death Induced by HIV-1, J. Biolog. And Homeostat. Agents, vol. 10, No. 1, pp. 13-18 (1996).
Casey S. Fu, Marian E. Swendseid, Robert A. Jacob, Ralph W. McKee, Biochemical Markers for Assessment of of Niacin Status in Young Men: Levels of Erythrocyte Niacin Coenzymes and Plasma Tryptophan, in the American Institute of Nutrition, 1989.
Werner ER, Fuchs D, Hausen A, et al. Tryptophan Degradation in Patients Infected by Human Immunodeficiency Virus, Biol Chem Hoppe Seyler 1988: 369(5):337-40.
Larsson M, Hagberg L, Norkrans G, Forsman A, Indole Amine Deficiency in Blood and Cerebrospinal Fluid From Patients With Human Immunodeficiency Virus Infection, J Neurosci Res, 1989; 23(4):441-6.
Fuchs D, Moller AA, Reibnegger G, Stockle E, Werner ER, Wachter H, Decreased serum Tryptophan in Patients With HIV-1 Infection Correlates With Increased Serum Neopterin and with Neurologic/psychiatric Symptoms, J Acquir Immune Defic Syndr, 1990; 3(9):873-6.
Fuchs D, Forsman A, Hagberg L, et al. Immune Activation and Decreased Tryptophan in Patients with HIV-1 Infection, J Interferon Res, 1990; 10(6):599-603.
Fuchs D,Moller AA, Reibnegger G, et al., Increased Endogenous Interferon-Gamma and Neopterin Correlate with Increased Degradation of Tryptophan in Human Immunodeficiency Virus Type 1 Infection, Immunol Lett, 1991; 28(3):207-11.
Heyes MP, Brew BJ, Saito K, et al. Inter-relationships between Quinolinic Acid, Neuroactive Kynurenines, Neopterin and Beta 2-Microglobulin in Cerebrospinal Fluid and Serum of HIV-1-Infected Patients, J Neuroimmunol 1992; 40(1):71-80.
Hortin GL, Landtm, Powderly WG, Changes in Plasma Amino Acid Concentrations in Response to HIV-1 Infection, Clin Chem 1994; 40(5):785-9.
Laurichesse H, Tauverson I. Gourdon F, et al. Threonine and Methionine are Limiting Amino Acids for Protein Synthesis in Patients with AIDS, J Nutr 1998; 128(8): 1342-8.
Huengsberg M, Winer JB, Gompels M, Round R, Ross J, Shahmanesh M, Serum Kynurenine-to-tryptophan Ratio Increases with Progressive Disease in HIV-Infected Patients, Clin Chem 1998; 44(4): 858-62.
Fu Casey S, Swendseid M, Jacob Robert, McKee Ralph, Biochemical Markers for Assessment of Niacin Status in Young Men: Levels of Erythrocyte Niacin Coenzymes and Plasma Tryptophan, American Institute of Nutrition, 1989, 1949-1955.
Ellis & Venable P.C.
Meaney Joseph R.
The Foundation For Innovative Therapies, Inc.
Wang Shengjun
LandOfFree
Treatment of retrovirus induced derangements with niacin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of retrovirus induced derangements with niacin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of retrovirus induced derangements with niacin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3549685